Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Net Income

Bottom-line profit after all expenses, interest, and taxes.

Grifols, S.A.NASDAQ: GRFS

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of €154M rose 31.6% year over year, behind the +52.1% change in trailing-twelve-month net income. Sequentially, it rose 107.5% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.

Context

  • Net income amounted to 5.3% of revenue in FY2025, up 3.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of €594.86M (+54.1%) for the fiscal year ending Dec 2026, a slowdown from the +146.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€154M+107.5% QoQ
Last fiscal yearDec 2025
€386.13M+146.1% YoY
LTMJun 2026
€452.49M+52.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.6%+53.7%+22.1 pp
1 year+146.1%+54.1%-92.0 pp
3-year CAGR+27.8%+34.8%+7.0 pp
5-year CAGR+24.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
386.13M EUR
Year-over-year change
+146.1%
4-year CAGR
+19.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +52.1% is the 3rd highest of 9, against a peer median of -31.1%.
  • Net income amounts to 6.1% of revenue for GRFS, versus a peer median of 11.9%.
GRFS Competitors
Net Income for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$4.7B USD-66.4%-2.0%9.7%
BDXBecton, Dickinson and CompanyLTM Sep 2026$1.14B USD-31.8%-8.3%5.7%
GRFSGrifols, S.A.LTM Jun 2026€452.49M EUR+52.1%+27.8%6.1%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$222.4M USD-30.3%—8.6%
TECHBio-Techne CorporationLTM Sep 2026$171.97M USD+120.5%-13.9%14.0%
ADMAADMA Biologics, Inc.LTM Jun 2026$168.96M USD-19.1%—33.0%
HAEHaemonetics CorporationLTM Jun 2026$96.29M USD-41.1%-5.5%7.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$77.39M USD+60.3%—37.1%
QDELQuidelOrtho CorporationLTM Mar 2026-$1.21B USD-237.6%—45.6%
Peer median (excluding GRFS) —-31.1%-6.9%11.9%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.